rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Kyntra Bio, Inc.

KYNB · Nasdaq

Health CareBiotechnologyNot moving yet

KYNB stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 40 weeks. It is 25.9% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−12 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 40
Industry in uptrend
18% -12 in 4 wk
Insider buys, 12 months
$113K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
24 (-5)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

22 Apr – 21 Oct
16%27%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$150KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4
Sale orders, 12 months0
Buyers · sellers1 · 0
WhoDidSharesTraded
Thane WettigCEObought2,800at $7.0914 May 2026filed 18 May 2026
Thane WettigCEObought2,800at $7.0914 May 2026filed 19 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders24-5 on the quarter
New · exited1 · 6
Reported value$6.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ARMISTICE CAPITAL, LLCunchanged · filed 14 Aug 2026400,000$3.0M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026159,950$1.2M+3,343+2.1%
BlackRock, Inc.reduced · filed 7 Aug 202684,330$637K-10.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202643,219$326K-2,779−6.0%
HighTower Advisors, LLCadded · filed 5 Aug 202639,746$300K+20.0%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 202639,511$298K-10,000−20.2%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 202627,081$204K-400−1.5%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202624,105$182K+163+0.7%
Birchview Capital, LPunchanged · filed 14 Aug 202622,566$170K00.0%
STATE STREET CORPunchanged · filed 7 Aug 202620,284$153K00.0%
30 Jun 2025 – 30 Jun 2026
242831Jun 25Sep 25Dec 25Mar 26Jun 26

Everyone who traded it

Andrew E. Singer Company insiderDirector · last 1 Oct 20260 · 0
David DeLucia Company insiderChief Financial Officer · last 6 Sep 20260 · 0
Thane Wettig Company insiderCEO · last 6 Sep 20267 · 8
James A. Schoeneck Company insiderDirector · last 12 Jun 20263 · 8
Jeffrey L. Edwards Company insiderDirector · last 12 Jun 20260 · 1
Maykin Ho Company insiderDirector · last 12 Jun 20260 · 1
Michael Kauffman Company insiderDirector · last 12 Jun 20260 · 0
Christine Chung Company insiderSVP, CHINA OPERATIONS · last 6 Mar 20250 · 30
Juan Graham Company insiderCHIEF FINANCIAL OFFICER · last 7 Dec 20240 · 8
Deyaa Adib Company insiderChief Medical Officer · last 12 Jun 20241 · 0
Aoife Brennan Company insiderDirector · last 5 Jun 20240 · 1
Benjamin Cravatt Company insiderDirector · last 5 Jun 20240 · 1

Same industry

MRNA ModernaLeading+168%
ENTX Entera BioLeading+53%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202591.4%
Operating profit marginFY 2025 · to 31 Dec 2025-713%
Free cash flow marginFY 2025 · to 31 Dec 2025-74.7%
Return on capital employedFY 2025 · to 31 Dec 2025-50.8%
Cash conversionFY 2025 · to 31 Dec 2025-2.6%
Interest coverFY 2025 · to 31 Dec 2025-5.24×
Research spendFY 2025 · to 31 Dec 2025365%
Share count trendFY 2025 · to 28 Feb 2026-0.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$47.9M
Free cash flowFY 2025 · to 31 Dec 2025−$4.8M

Analyst forecasts

No analyst forecasts yet.